Dr. Florian von Baum
Rechtsanwalt, Partner, Sector Head Technology, Science & Industry
Our global team of advisers support TMT and IP-rich industries around the world being redefined by digital transformation, including Diversified Industrials, Healthcare, Life Sciences and Technology & Digital Markets.
Dr. Florian von Baum, Head of our Technology, Science & Industry sector, discusses the challenges and opportunities for organisations in the sector.
Our advisers act on domestic and international projects of all shapes and sizes, working with many of the leading names across this diverse sector. Browse our experience below, or use the filters to look-up recent work in particular geographies and legal disciplines.
Partner, Head of Diversified Industrial
Nicole advises both listed and unlisted companies on all aspects of domestic and cross-border M&A transactions and joint ventures.
Partner, Head of IP & Life sciences
Clare leads Pinsent Masons’ IP and Life Sciences teams.
Partner, Head of Healthcare
Joanne is head of the Health sector but sits within the Corporate Group, specialising principally in private company and private equity work including acquisitions and disposals, buy-in and buy-outs, joint ventures and investments.
Our expertise, at your disposal
With over 430 partners and 3000 people around the world, we are well-placed to support you across a full range of legal and advisory services.
Art collector's court case signals potential legal and contractual issues with NFTs
Multinational law firm Pinsent Masons has advised Wesleyan Assurance Society on its sale of Wesleyan Bank Limited and subsidiaries to Hampshire Trust Bank plc, subject to regulatory approval.
Multinational law firm Pinsent Masons has advised Malaysian utility, TNB and Vantage RE, its UK/European arm, on its acquisition of a 49% stake in the offshore wind farm company Blyth Offshore Demonstrator Limited (BODL) from EDF Renewables.
Multinational law firm Pinsent Masons has advised the UK government on its contracts for the purchase of significant volumes of two novel, Covid-19 specific, antivirals.